17-beta estradiol
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT02677259 | May 2016 → Jun 2018 | — | One Fertility | Unknown | No outcome recorded |
| Phase 2 | NCT00059228 | Apr 2003 → Nov 2016 | postpartum depression | National Institute of Mental Health (NIMH) | Terminated | No outcome recorded |
| Phase 2 | NCT00332553 | Feb 2002 → May 2004 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT06530459 | Aug 2024 → Apr 2027 expected | arthropathy, menstrual disorder | National University Hospital, Singapore | Recruiting | No outcome recorded |
| Phase 2/3 | NCT00204074 | Oct 2001 → Jul 2005 | migraine disorder | University Hospital, Linkoeping | Unknown | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT06851754 | Jul 2025 → Dec 2031 expected | primary ovarian failure | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Recruiting | No outcome recorded |
| Phase 3 | NCT00946192 | May 2009 → Feb 2020 | functional hypothalamic amenorrhea | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00140998 | Jan 2001 → Jun 2004 | Turner syndrome | Nemours Children's Clinic | Completed | No outcome recorded |
| Phase 3 | NCT01710696 | Jul 1998 → Jul 2004 | Turner syndrome | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06508944 | Apr → Oct 2024 | female stress incontinence, overactive bladder, postmenopausal atrophic vaginitis, urethral disorder | Mahidol University | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT00113100 | Aug 2004 → Jun 2007 | wrinkly skin syndrome | University of Michigan | Completed | No outcome recorded |
| — | NCT00123539 | Jun 2001 → Aug 2005 | coronary artery disorder | National Heart, Lung, and Blood Institute (NHLBI) | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 10 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT05010707 Comparator | Aug 2021 → Aug 2023 | — | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT03018366 Comparator | Jan 2017 → Feb 2023 | cardiovascular disorder, functional hypothalamic amenorrhea | Cedars-Sinai Medical Center | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00236301 Comparator | Mar 2004 → Jun 2006 | — | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT05428215 Comparator | Dec 2022 → Jul 2023 | body integrity dysphoria | MaineHealth | Terminated | No outcome recorded |
| Phase 4 | NCT06570460 Comparator | Nov 2021 → Dec 2026 expected | Turner syndrome | Aarhus University Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06544473 Comparator | Nov 2021 → Dec 2026 expected | Turner syndrome | Aarhus University Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT01489852 Comparator | Dec 2006 → Jul 2010 | infertility disorder | Gemer | Completed | No outcome recorded |
| Phase 4 | NCT01518062 Background | Nov 1989 → Sep 2003 | Turner syndrome, autosomal genetic disease | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT02086032 Background | Jan 2014 → Jun 2015 | — | Chiang Mai University | Completed | No outcome recorded |
| — | NCT01023178 Comparator | Feb 2007 → Jun 2013 | primary ovarian failure | Stanford University | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 28 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 17 beta-estradiol | “participants with POI (n=85) will receive transdermal 17 beta-estradiol (beginning at a dose of 25 microgram/patch applied weekly), with the dose increased at 3 months to 50...” NCT06851754 ↗24“This open label, pilot, randomized clinical trial will evaluate the effectiveness and safety of gender affirming hormone therapy with estrogen and the degree of testosterone...” NCT05010707 ↗ “prospectively randomized to receive 17beta-estradiol or placebo in a double-blind manner beginning the day before surgery and continuing for 5 days postoperatively.” PMID 19224775 ↗ Mar 2009 “Menopausal hormone therapy comprising: 17beta-estradiol topical gel (1.25-2.5 gms) applied daily, and micronized Progesterone 200mg daily for 12 days each month.” NCT06530459 ↗ “receive treatment with 100 microg 17-beta estradiol/placebo transdermally one week before the estimated start of the menstrual bleeding and twoo weeks on.” NCT00204074 ↗ “Apply 17 beta-Estradiol topical gel (1.25-2.5 gms) daily Ingest Micronized Progesterone 200mg daily for 12 days each month” NCT06530459 ↗ “After a minimum of 4 yr of GH treatment, low-dose micronized 17beta-estradiol was given orally.” PMID 12466334 ↗ Dec 2002 “combined treatment with raloxifene HCl 60 mg and oral 17 beta-estradiol 1mg/day” NCT00332553 ↗ “17beta-Estradiol will be administered to group A treatment arm intravaginally.” NCT06508944 ↗ |
| Known as | 17β-estradiol | “Randomization by sealed envelopes to receive 17β-estradiol (4 mg/d) or no pretreatment before daily recombinant FSH administration started on the first day of estrogen...” PMID 22464760 ↗ Mar 20123“Prevention of menstrual migraine with perimenstrual transdermal 17-β-estradiol: a randomized, placebo-controlled, double-blind crossover study.” PMID 21704313 ↗ Jun 2011 “a 100-μg 17β-estradiol transdermal patch (PATCH) administered continuously with 200 mg cyclic oral micronized progesterone” PMID 31603998 ↗ Nov 2019 “or transdermal 100 µg 17-β-estradiol patch” PMID 28297591 ↗ May 2017 |
| Known as | Estradiol | “Estradiol therapy has a prophylactic effect in women at high risk for developing PPD” NCT00059228 ↗ |
| Known as | OBE | “The purpose of this study was to compare the differential effects of treatment with oral conjugated equine estrogen (OCEE), oral 17β estradiol (OBE), or transdermal 17β...” PMID 24982681 ↗ Jun 2014 |
| Known as | Provames | “Pretreatment with 17beta-estradiol (Provames®, Aventis, Paris, France) was administered daily (2 mg twice a day) during the cycle preceding the IVF/ICSI cycle, starting 7 days...” NCT01489852 ↗ |
| Known as | TBE | “The purpose of this study was to compare the differential effects of treatment with oral conjugated equine estrogen (OCEE), oral 17β estradiol (OBE), or transdermal 17β...” PMID 24982681 ↗ Jun 2014 |
| Route | Topical | “Interventions Topical application of estradiol, 0.01%, 0.1%, 1%, or 2.5% or vehicle on aged or photoaged skin” PMID 18794456 ↗ Sep 2008 |